If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
CoAxia Reaches 515 Patients Enrolled in its SENTIS Pivotal Study MINNEAPOLIS, Feb. 12 (HSMN NewsFeed) — CoAxia, Inc. of Maple Grove, MN, announced today the completion of enrollment in its SENTIS randomized, controlled, pivotal trial of NeuroFlo Perf…
Devices, Interventional, Neurology
CoAxia , NeuroFlo, Perfusion Augmentation Therapy, stroke
Posts from ‘February, 2010’
CoAxia Announces Completion of Enrollment in Ischemic Stroke Trial
NewLink Genetics Receives Special Protocol Assessment Approval from FDA for Pivotal Phase THREE Trial in Pancreatic Cancer
AMES, Iowa, Feb. 11 (HSMN NewsFeed) — NewLink Genetics Corporation announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a pivotal Phase 3 trial of its HyperAcute…
Biopharmaceuticals, Oncology, FDA
NewLink Genetics, HyperAcute, immunotherapy, pancreatic cancer
German Appellate Court Affirms Edwards Lifesciences’ Transcatheter Valve Patent Not Infringed by CoreValve
IRVINE, CA–(HSMN NewsFeed) - Edwards Lifesciences Corporation (NYSE:EW ), the world leader in the science of heart valves and hemodynamic monitoring, announced today that the Appellate Court of Dusseldorf, Germany, has affirmed a lower court decision that…
Devices, Cardiology, Litigation
Edwards Lifesciences, CoreValve, transcatheter heart valve, heart valve
OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
HONG KONG, Feb. 11 (HSMN NewsFeed) — OrbusNeich today announced that the first patient has been enrolled in a randomized clinical trial of the Genous Bio-engineered R stent in China. A multicenter, randomized, controlled study, the trial will enroll …
Devices, Interventional Cardiology
OrbusNeich, Genous, Bio-engineered R stent
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
ABBOTT PARK, Ill., Feb. 11 (HSMN NewsFeed) — Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a new tablet formulation of the company’s antiretroviral medication Norvir ® (ritonavir). The n…
Biopharmaceuticals, HIV/AIDS, FDA
Abbott, Norvir, ritonavir, Kaletra, lopinavir
New Scientific Publication Highlights Long-Term Survival of Brain Cancer Patients Treated With Peregrine Pharmaceuticals’ Cotara(R)
Article in Current Cancer Therapy Reviews Reports on GBM Patients Who Have Survived More than Nine Years after Treatment with Cotara TUSTIN, Calif., Feb. 11 (HSMN NewsFeed) — Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported publication o…
Biopharmaceuticals, Oncology
Peregrine Pharmaceuticals, Cotara, glioblastoma multiforme
Excelimmune Receives $1 Million in Series-B Funding
WOBURN, Mass.–(HSMN NewsFeed)–Excelimmune, Inc. announced today they have received a $1 million investment as part of an open Series-B financing round. The investment comes from a mixture of existing and new investors. Proceeds from the financing will be…
Biopharmaceuticals, Venture Capital
Excelimmune
OXiGENE Announces Restructuring to Focus Resources on Key Programs and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2010 –(HSMN NewsFeed) — OXiGENE, Inc. (Nasdaq:OXGN ) (Stockholm:OXGN ), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today a restructuring plan…
Biopharmaceuticals
OXiGENE
NEJM Publishes Trial Results Demonstrating Bard FLAIR(R) Endovascular Stent Graft is Superior to Balloon Angioplasty for Failing Dialysis Grafts
MURRAY HILL, N.J.–(HSMN NewsFeed)–C. R. Bard, Inc. (NYSE: BCR ) today announced the publication of trial results by The New England Journal of Medicine (NEJM) showing the Bard FLAIR® Endovascular Stent Graft maintains the patency of dialysis access g…
Devices, Interventional
C. R. Bard, Endovascular Stent Graft, dialysis access graft
Boston Scientific Announces Management Changes and Restructuring Initiatives
New structure, leadership team and targeted portfolio changes will focus on sales excellence and cost effectiveness NATICK, Mass., Feb. 10 (HSMN NewsFeed) — Boston Scientific Corporation (NYSE: BSX) today announced a series of management changes and …
Devices, Interventional, Cardiology, Personnel
Boston Scientific
